Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ZonMw: The Netherlands Organisation for Health Research and Development | OTHER |
Not provided
Not provided
Not provided
A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level of 3.9-10.0 mmol/L, to reduce the number of surgical site infections within the first 30 days postoperatively in adult patients with diabetes mellitus type 2.
People with type 2 diabetes mellitus (PWT2D) are at increased risk of postoperative complications, especially surgical site infections (SSI).
The aim of this study to reduce SSI in PWT2D by implementing a proactive basal-bolus insulin regimen, compared to the reactive sliding scale regimen.
Adult patients with type 2 diabetes will be included in this multi-centre study.
Participants will receive a blind CGM, i.e. glucose data are masked for the participants and study team, from admission to the ward until discharge from the hospital. In addition, all participants are asked to complete several questionnaires 30 days after surgery.
Both regimens are currently used in clinical practice. Therefore, there is no additional trial-related burden depending on the intervention group allocation.
Participants will be monitored intensively and insulin dosage will be adjusted adequately to the measured glucose values by the treatment team.
The sample size is based on the SSI incidence rates. Wards are matched into pairs with comparable baseline incidence rates and in each pair, one ward will be randomly assigned to the intervention group; the other serves as the control. 18 wards from 8 participating centres are planned to be recruited, this translates to 9x2x56=1008 evaluable participants.
Keywords:
Diabetes mellitus, basal bolus, sliding scale, insulin regimen, surgical site infections
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Basal Bolus | Experimental | Patients daily dose of insulin is calculated by their treatment team: In insulin naive patients 0.4-0.5IU/kg and 0,3IU/kg for patients aged>70 or patients with impaired kidney function with an estimated glucose filtration rate <60ml/min and 80-100% of own insulin for insulin-users. They receive half of this daily dose in long-acting insulin once a day. The other half of their total daily dose of insulin is provided as short-acting mealtime insulin. This short-acting insulin is administered before each meal. When needed, extra insulin can be given when needed. The measurements of blood glucose values are before each meal and at bedtime (4x/day). |
|
| Sliding Scale | No Intervention | Short-acting insulin is administered when blood glucose value is above 10,0 mmol/L according to a standardized dosage schedule. The measurements of blood glucose values are before each meal and at bedtime (4x/day). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Basal bolus insulin regimen | Other | Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively |
|
| Measure | Description | Time Frame |
|---|---|---|
| Surgical site infection | Incidence of postoperative surgical site infection, according to the criteria of the centres of disease control (CDC) for superficial incisional SSI, deep incisional SSI and organ / space SSI. SSIs will be measured at 30 days postoperatively via BLUEBELLE questionnaire, diagnosis by surgeon during standard postoperative visit at the surgery clinic 3-5 weeks after surgery and chart review. | Until 30 days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative hospital-acquired infections (non-SSI) | Incidence of hospital-acquired infections, other than surgical site infections | Recorded at 30 days postoperatively |
| Length of stay in the hospital (LoS-Hos) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ayla Y. Stobbe, MD | Contact | 0031205669111 | a.y.stobbe@amsterdamumc.nl | |
| Sarah E. Siegelaar, MD, PhD | Contact | 0031205669111 | s.e.siegelaar@amsterdamumc.nl |
| Name | Affiliation | Role |
|---|---|---|
| Sarah E. Siegelaar, MD, PhD | Amsterdam UMC, location AMC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amsterdam UMC | Recruiting | Amsterdam | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24111757 | Background | Kao LS, Phatak UR. Glycemic control and prevention of surgical site infection. Surg Infect (Larchmt). 2013 Oct;14(5):437-44. doi: 10.1089/sur.2013.008. Epub 2013 Oct 10. | |
| 25133932 | Background | Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, Flum DR; SCOAP-CERTAIN Collaborative. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg. 2015 Jan;261(1):97-103. doi: 10.1097/SLA.0000000000000688. |
Not provided
Not provided
Complete data collection methods and results will be shared with other researchers upon a formal request made to the principal investigator including a detailed motivation for the request.
One year after reviewed publication of the primary results
Official request to the principal investigator
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D013530 | Surgical Wound Infection |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Multicenter, matched, cluster-randomised
Not provided
Not provided
Not provided
Not provided
Length of stay in the hospital, measured in days from admission to discharge from the hospital.
| Recorded at 30 days postoperatively |
| Hospital readmission | Rate of hospital readmissions within 30 days after surgery | Recorded 30 days postoperatively |
| Days at home (DAH30) | Patient-reported number of days at home after surgery, between 0 and 30. | Recorded 30 days postoperatively |
| Postoperative disability | Patient-reported level of disability 30 days after surgery, using the WHODAS-2.0 questionnaire. Summarized in a score between 0-100. | Recorded 30 days postoperatively |
| Quality of life (QoL) after surgery | Patient-reported health-related quality of life 30 days after surgery, using the EuroQol 5D5L questionnaire, summarized in a score between 0 and 1. | Recorded 30 days postoperatively |
| Glucose 2 | Incidence of grade 2 hypoglycemia, a blood glucose below 3.0mmol/L. | Measured 4 times a day, until discharge from the hospital, up to 30 days. |
| Glucose 3 | Incidence of grade 1 hyperglycemia, a blood glucose above 10.0mmol/L. | Measured 4 times a day, until discharge from the hospital, up to 30 days. |
| Glucose 4 | Incidence of grade 2 hyperglycemia, a blood glucose above 14.0mmol/L. | Measured 4 times a day, until discharge from the hospital, up to 30 days. |
| CGM1 | Percentage of time within glycaemic target range (3.9-10.0 mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM). | Measured with a 5-minute interval, until discharge from the hospital, up to 30 days. |
| CGM2 | Percentage of time below glycaemic target range (<3.9mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM). | Measured with a 5-minute interval, until discharge from the hospital, up to 30 days. |
| CGM3 | Percentage of time above glycaemic target range (>10.0mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM). | Measured with a 5-minute interval, until discharge from the hospital, up to 30 days. |
| Cost-effectiveness 1 | The cost-effectiveness of the basal bolus insulin regimen compared to the sliding scale regimen, considering the costs per prevented of SSI in a cost-effectiveness analysis. | Until 30 days after surgery |
| Cost-effectiveness 2 | The number of quality adjusted life years (QALYs) gained after a cost-utility analysis. | Up to 30 days after surgery. |
| Protocol adherence | The adherence to the protocol until discharge from the hospital | During the hospital stay, until discharge |
| 25592489 | Background | Polderman JA, Van Velzen L, Wasmoeth LG, Eshuis JH, Houweling PL, Hollmann MW, Devries JH, Preckel B, Hermanides J. Hyperglycemia and ambulatory surgery. Minerva Anestesiol. 2015 Sep;81(9):951-9. Epub 2015 Jan 16. |
| 27901264 | Background | de Vries FE, Gans SL, Solomkin JS, Allegranzi B, Egger M, Dellinger EP, Boermeester MA. Meta-analysis of lower perioperative blood glucose target levels for reduction of surgical-site infection. Br J Surg. 2017 Jan;104(2):e95-e105. doi: 10.1002/bjs.10424. Epub 2016 Nov 30. |
| 21228246 | Background | Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011 Feb;34(2):256-61. doi: 10.2337/dc10-1407. Epub 2011 Jan 12. |
| 19398246 | Background | de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control. 2009 Jun;37(5):387-397. doi: 10.1016/j.ajic.2008.12.010. Epub 2009 Apr 23. |
| 28660256 | Background | Phillips VL, Byrd AL, Adeel S, Peng L, Smiley DD, Umpierrez GE. A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens. Pharmacoecon Open. 2017;1(2):109-115. doi: 10.1007/s41669-017-0020-9. Epub 2017 Apr 21. |
| 31330166 | Background | Koek MBG, van der Kooi TII, Stigter FCA, de Boer PT, de Gier B, Hopmans TEM, de Greeff SC; Burden of SSI Study Group. Burden of surgical site infections in the Netherlands: cost analyses and disability-adjusted life years. J Hosp Infect. 2019 Nov;103(3):293-302. doi: 10.1016/j.jhin.2019.07.010. Epub 2019 Jul 19. |
| 34949439 | Background | Fowler AJ, Wahedally MAH, Abbott TEF, Smuk M, Prowle JR, Pearse RM, Cromwell DA. Death after surgery among patients with chronic disease: prospective study of routinely collected data in the English NHS. Br J Anaesth. 2022 Feb;128(2):333-342. doi: 10.1016/j.bja.2021.11.011. Epub 2021 Dec 20. |
| 19465235 | Background | Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009 May 23;373(9677):1798-807. doi: 10.1016/S0140-6736(09)60553-5. |
| 35402490 | Background | Lai J, Li Q, He Y, Zou S, Bai X, Rastogi S. Glycemic Control Regimens in the Prevention of Surgical Site Infections: A Meta-Analysis of Randomized Clinical Trials. Front Surg. 2022 Mar 25;9:855409. doi: 10.3389/fsurg.2022.855409. eCollection 2022. |
| 30488948 | Background | Colunga-Lozano LE, Gonzalez Torres FJ, Delgado-Figueroa N, Gonzalez-Padilla DA, Hernandez AV, Roman Y, Cuello-Garcia CA. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. Cochrane Database Syst Rev. 2018 Nov 29;11(11):CD011296. doi: 10.1002/14651858.CD011296.pub2. |
| 24623024 | Background | Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Sugimoto T, Kobayashi M, Yokoyama M, Hanazaki K. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care. 2014 Jun;37(6):1516-24. doi: 10.2337/dc13-1771. Epub 2014 Mar 12. |
| 26084869 | Background | Yuan J, Liu T, Zhang X, Si Y, Ye Y, Zhao C, Wang Q, Shen X. Intensive Versus Conventional Glycemic Control in Patients with Diabetes During Enteral Nutrition After Gastrectomy. J Gastrointest Surg. 2015 Aug;19(8):1553-8. doi: 10.1007/s11605-015-2871-7. Epub 2015 Jun 18. |
| 17513708 | Background | Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007 Sep;30(9):2181-6. doi: 10.2337/dc07-0295. Epub 2007 May 18. |
| 34328842 | Background | Migdal AL, Fortin-Leung C, Pasquel F, Wang H, Peng L, Umpierrez GE. Inpatient Glycemic Control With Sliding Scale Insulin in Noncritical Patients With Type 2 Diabetes: Who Can Slide? J Hosp Med. 2021 Aug;16(8):462-468. doi: 10.12788/jhm.3654. |
| 35690958 | Background | Korytkowski MT, Muniyappa R, Antinori-Lent K, Donihi AC, Drincic AT, Hirsch IB, Luger A, McDonnell ME, Murad MH, Nielsen C, Pegg C, Rushakoff RJ, Santesso N, Umpierrez GE. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022 Jul 14;107(8):2101-2128. doi: 10.1210/clinem/dgac278. |
| D014946 | Wound Infection |
| D007239 | Infections |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |